$CGEN

Compugen Ltd Q2 Loss Drops

Compugen Ltd (CGEN) reported a Q2 GAAP net loss of $7.01 million, or $0.07 per share, improving from a $7.34 million loss, or $0.08 per share, a year earlier. Revenue rose 106.3% to $2.60 million from $1.26 million, according to the company.

Original reporting
Published Aug 3, 2026, 11:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 12:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CGEN
Bearish
medium confidence
Mentioned
$CGEN
Relevance
5/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$CGENBearishLow
01

Why it matters

Investors will likely weigh the large year-over-year revenue increase against the still-material GAAP net loss of $7.01M.

02

Market read

This is a straightforward earnings datapoint with revenue growth but continued losses, offering limited incremental decision-making without guidance or cash-flow context.

03

What to watch

No cash balance, operating expense trend, guidance, or backlog is provided, so the market may need additional filings to judge whether losses are controllable.

Relevance 5/10Novelty 5/10Timing: Q2 results reported today (2026-08-03)

Background

The article summarizes Compugen’s Q2 GAAP results, comparing them to the prior year.

Company-level read

Ticker impact

$CGENBearishMedium confidence
Context

Compugen reported Q2 GAAP net loss of $7.01M, with revenue up 106.3% to $2.60M, versus prior-year $1.26M.

Expected impact

Likely downside or choppy trading if investors focus on losses outweighing revenue growth.

Evidence & confidence

The article provides only GAAP loss and revenue growth, with no guidance or balance-sheet/cash detail to offset the loss trend.

Market effects

Limited read-through because the article lacks segment, customer, or product details beyond revenue and GAAP loss.

None indicated.

None indicated.

Counterpoint

Revenue more than doubled year over year, which could indicate improving traction that may eventually reduce losses if costs scale slower.

Key entities

  • Compugen Ltd

    Reported Q2 GAAP net loss of $7.01M and revenue of $2.60M, up 106.3% year over year.

Related articles

$CGENMed

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.

$TSLAHighAI 9/10

Tesla Posted Negative $1.1 Billion in Free Cash Flow Last Quarter as Elon Musk Ramps Up Spending on Robotaxis and Optimus. Here's Why the Company's $43.5 Billion Cash Cushion Still Matters.

Tesla reported a 26% revenue increase to $22.5B in Q2, with net income of $1.11B, but negative free cash flow of $1.1B due to $5.79B in capital expenditures. The company's $43.5B cash position provides a buffer for growth investments in robotaxis, Optimus robots, and semiconductors. Tesla's market share in U.S. EVs has risen despite industry contraction, but competition from Chinese rivals like BYD persists.

$BWINMed

Michael Dell Just Made a $7.7 Billion Bet on This Insurance Stock

Michael Dell is acquiring Baldwin & Co. (BWIN) for $7.7B. Baldwin reported Q2 revenue of $492.9M (+30% YoY), adjusted net income of $68.5M, and adjusted EBITDA of $116.7M (+37%). Management guided Q3 revenue to $485M-$495M and full-year revenue to $2.01B-$2.05B. Analysts have mixed targets, with a consensus 'Moderate Buy' and average target of $33.

$AMZNMedAI 8/10

Should You Buy Amazon Stock For The Demand AWS Cannot Yet Serve?

Amazon.com (AMZN) stock is down 13% from its 52-week high, despite AWS's 36.7% YOY revenue growth in Q2 2026. AWS's backlog of committed contracts reached $496 billion, with demand outpacing capacity. AWS's operating margin improved 520 basis points YOY, excluding energy contract gains. Management attributes growth to AI workloads and efficient capacity use.

$ASMLMedAI 8/10

Weakness Is an Opportunity for Long-Term ASML Stock Investors

ASML's High-NA technology is gaining traction among chipmakers like Samsung, Intel, and TSMC, crucial for its long-term outlook. Q2 earnings beat estimates with €7.59 EPS and €9.33B revenue. ASML raised full-year 2026 sales guidance to €43B-€45B. Analysts have a consensus 'Hold' rating, with a mean price target of $2,350.75, implying 56% upside.